GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (NAS:APTO) » Definitions » ROA %

Aptose Biosciences (Aptose Biosciences) ROA % : -282.42% (As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Aptose Biosciences ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Aptose Biosciences's annualized Net Income for the quarter that ended in Dec. 2023 was $-47.82 Mil. Aptose Biosciences's average Total Assets over the quarter that ended in Dec. 2023 was $16.93 Mil. Therefore, Aptose Biosciences's annualized ROA % for the quarter that ended in Dec. 2023 was -282.42%.

The historical rank and industry rank for Aptose Biosciences's ROA % or its related term are showing as below:

APTO' s ROA % Range Over the Past 10 Years
Min: -204.42   Med: -65.54   Max: -44.65
Current: -169.05

During the past 13 years, Aptose Biosciences's highest ROA % was -44.65%. The lowest was -204.42%. And the median was -65.54%.

APTO's ROA % is ranked worse than
91.52% of 1556 companies
in the Biotechnology industry
Industry Median: -35.42 vs APTO: -169.05

Aptose Biosciences ROA % Historical Data

The historical data trend for Aptose Biosciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences ROA % Chart

Aptose Biosciences Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -44.79 -48.72 -62.60 -62.63 -159.98

Aptose Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -74.02 -121.08 -171.51 -192.99 -282.42

Competitive Comparison of Aptose Biosciences's ROA %

For the Biotechnology subindustry, Aptose Biosciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptose Biosciences's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptose Biosciences's ROA % distribution charts can be found below:

* The bar in red indicates where Aptose Biosciences's ROA % falls into.



Aptose Biosciences ROA % Calculation

Aptose Biosciences's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-51.207/( (51.027+12.989)/ 2 )
=-51.207/32.008
=-159.98 %

Aptose Biosciences's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-47.82/( (20.876+12.989)/ 2 )
=-47.82/16.9325
=-282.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Aptose Biosciences  (NAS:APTO) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-47.82/16.9325
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-47.82 / 0)*(0 / 16.9325)
=Net Margin %*Asset Turnover
=N/A %*0
=-282.42 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Aptose Biosciences ROA % Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptose Biosciences (Aptose Biosciences) Business Description

Traded in Other Exchanges
Address
251 Consumers Road, Suite 1105, Toronto, ON, CAN, M2J 4R3
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Executives
Bernd R. Seizinger director 535 BOYLSTON STREET, BOSTON MA 02116
William G. Rice director, officer: Chair, President & CEO C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Fletcher Payne officer: SR VP & Chief Fin. Officer 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Philippe Ledru officer: Chief Commercial Officer C/O APTOSE BIOSCIENCES INC., 2511 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Denis R Burger director CYTODYN INC., 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Erich Platzer director
Rafael Bejar officer: Chief Medical Officer C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Wilson Donald R. Jr. 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Holdings, Llc 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Commodities, Llc 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Warren Whitehead director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Gregory K. Chow officer: Senior VP & CFO C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Jotin Marango officer: Senior VP, Chief Bus. Officer C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Mark D. Vincent director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3